publication date: Jul. 6, 2018

CTEP Protocols

NCI Trials for July

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. 

For further information, contact the principal investigator listed.


Phase I – 10145

Phase Ib Combination Study of Copanlisib and Nivolumab in Advanced Solid Tumors and Lymphomas

National Cancer Institute LAO

O’Sullivan Coyne, Geraldine

(301) 402-9122


Phase I/II – 10106

A Phase I and Randomized Phase II Study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in Relapsed and Refractory Lymphomas

JHU Sidney Kimmel Comprehensive Cancer Center LAO

Kumar, Anita

(212) 639-2668


Phase I/II – 10150

A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer

University Health Network Princess Margaret Cancer Center LAO

Lheureux, Stephanie

(416) 946-4501 X 2415


Phase II – 10147

A Phase II Randomized Study of Topotecan/Carboplatin with or Without Veliparib in Advanced Myeloproliferative Disorders and Chronic Myelomonocytic Leukemia (CMML)

JHU Sidney Kimmel Comprehensive Cancer Center LAO

Pratz, Keith William

(410) 502-7726


Phase II – APEC1621I

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes

Children’s Oncology Group

Mody, Rajen

(734) 764-7126

Continue reading NCI Trials for July 2018
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.